SV

Street Verdict

Analyst Scorecard

A record of what Dipan Mehta said publicly, with the source. Not advice.

Pending — not yet graded
“Bullish on the pharma sector, recommending an overweight position for investors. He anticipates early positive surprises on the earnings front, providing comfort that strong earnings growth will come through, which is currently lacking in many other sectors.”
Nifty PharmaBullishCalled 24 Oct 2024
Verdict:PENDING

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Read the original articleSee Dipan Mehta’s full track record